UCB licenses AI technology to ImageBiopsy Lab

2020 07 14 15 45 4340 Osteoporosis Hip Joint 400

UCB Pharma will license its artificial intelligence (AI) technology, which is designed to improve osteoporosis identification, to ImageBiopsy Lab, the Vienna-based company.

ImageBiopsy Lab, the winner of the 2021 Best New Vendor in the EuroMinnies awards scheme, plans to develop and launch an AI-based fracture identification tool based on UCB's BoneBot technology. BoneBot uses artificial intelligence to detect the presence of asymptomatic fractures in the spine.

Furthermore, UCB's BoneBot technology will be integrated with ImageBiopsy Lab's ZOO MSK platform and be delivered to hospitals to help to increase the reporting of spinal fractures.

Page 1 of 110
Next Page